Related Experiment Videos
Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary
K Ishikawa1, K Kanamasa, J Hama
1First Department of Internal Medicine, Kinki University, School of Medicine, Osaka, Japan.
Insights
Combining low-dose aspirin with antiplatelet agents significantly reduces cardiac events in myocardial infarction survivors. This combination therapy offers a protective strategy against recurrent heart problems.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Myocardial infarction (MI) survivors are at high risk for recurrent cardiac events.
- Existing treatments may not fully mitigate this risk, necessitating further investigation into effective therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of combining low-dose aspirin with other antiplatelet agents in preventing cardiac events in patients with a history of MI.
Main Methods:
- A randomized study involving 1,083 patients with prior MI.
- Patients were divided into groups receiving antiplatelet therapy (aspirin plus dipyridamole or ticlopidine) or no antiplatelet therapy.
- Cardiac events were monitored over an average follow-up period of 12.5 months.
Main Results:
- The group receiving antiplatelet agents experienced significantly fewer cardiac events (3.1%) compared to the non-treatment group (7.3%; p < 0.01).
- Specific combinations, such as aspirin with dipyridamole or aspirin with ticlopidine, showed significant risk reduction (odds ratio 0.28 for both).
- Subgroup analyses confirmed the efficacy of these antiplatelet regimens, independent of patient background differences.
Conclusions:
- Combined therapy with low-dose aspirin plus dipyridamole or ticlopidine is effective in preventing cardiac events in patients with prior myocardial infarction.
- This therapeutic approach represents a valuable strategy for secondary prevention in post-MI patients.
- Further research may explore optimal combinations and long-term outcomes.
Abstract:
The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined. A total of 1,083 patients with prior myocardial infarction were randomly divided into those who were (618) and were not (465) treated with antiplatelet agents, and observed for 12.5 +/- 18.5 months. Those treated with antiplatelet agents included 113 patients treated with aspirin (50 mg) plus dipyridamole (150 mg/day), 253 treated with aspirin (50 mg) plus ticlopidine (200 mg/day), and 252 treated with only 1 of the 3 antiplatelet agents. Cardiac events, including fatal or nonfatal recurrent myocardial infarction, death by congestive heart failure, and sudden death, occurred in 34 patients (7.3%) in the nontreatment group and in 19 patients (3.1%; p < 0.01) in the treatment group; odds ratio 0.40, 95% confidence interval 0.23-0.71. There were only 2 cardiac events (1.8%) in the aspirin + dipyridamole group (p < 0.05 vs nontreatment group: odds ratio 0.28: 0.08-1.03), and 5 such events (2.0%) in the aspirin + ticlopidine group (p < 0.01; odds ratio 0.28: 0.11-0.69). Subgroup analysis to exclude differences in the patients' background confirmed the efficacy of these antiplatelet agents. We conclude that combined treatment with low doses of aspirin plus either dipyridamole or ticlopidine is effective in preventing cardiac events in patients who have had prior myocardial infarction.